Biotech & Health

Virtual physical therapists Hinge Health files for IPO, estimated to raise $500M

Biotech & Health /

Hinge Health, a 10-year-old company that offers a digital solution to treat chronic musculoskeletal (MSK) conditions, filed to go public. Although Hinge has not yet announced how many shares, nor priced them, the IPO specialists at Renaissance Capital estimate the company hopes to raise up to $500 million in its offering. Hinge’s revenue in 2024 […]

Virtual physical therapists Hinge Health files for IPO, estimated to raise $500M Read More »

Radiology AI software provider Gleamer expands into MRI with two small acquisitions

Biotech & Health /

Medical imaging is a broad term that encompasses several distinct technologies. After working on AI-powered tools to enhance X-rays and mammographies, French startup Gleamer now aims to tackle magnetic resonance imaging (MRI). Instead of starting from scratch, Gleamer has acquired two startups that have already been working on AI-powered MRI analysis: Pixyl and Caerus Medical.

Radiology AI software provider Gleamer expands into MRI with two small acquisitions Read More »

Colossal CEO Ben Lamm says humanity has a ‘moral obligation’ to pursue de-extinction tech

Biotech & Health /

The CEO of Colossal, a startup that aims to use genetic editing techniques to bring back extinct species, including the wooly mammoth, assured audiences at SXSW that the company has no plans to create a real-life Jurassic Park — lest there was any doubt. “Modern conservation isn’t working […] and we’re gonna need a ‘de-extinction’

Colossal CEO Ben Lamm says humanity has a ‘moral obligation’ to pursue de-extinction tech Read More »

Not all cancer patients need chemo. Ataraxis AI raised $20M to fix that.

Biotech & Health /

Artificial intelligence is a big trend in cancer care, and it’s mostly focused on detecting cancer at the earliest possible stage. That makes a lot of sense, given that cancer is less deadly the earlier it’s detected. But fewer are asking another fundamental question: if someone does have cancer, is an aggressive treatment like chemotherapy

Not all cancer patients need chemo. Ataraxis AI raised $20M to fix that. Read More »

Not all cancer patients need chemo — Ataraxis AI raised $20M to personalize treatment

Biotech & Health /

Artificial intelligence is a big trend in cancer care, and it’s mostly focused on detecting cancer at the earliest possible stage. That makes a lot of sense, given that cancer is less deadly the earlier it’s detected. But fewer are asking another fundamental question: If someone does have cancer, is an aggressive treatment like chemotherapy

Not all cancer patients need chemo — Ataraxis AI raised $20M to personalize treatment Read More »

On a quest to revive the woolly mammoth, Colossal Biosciences has created a woolly mouse

Biotech & Health /

Colossal Biosciences, known for its outlandish goal to resurrect the woolly mammoth by 2028, is claiming steady progress. It’s evidence: Genetically engineering mice to have mammoth-like fur. To engineer the woolly mouse, the company’s scientists found mouse versions of mammoth genes and then used CRISPR to edit mice embryos, Dr. Beth Shapiro, chief science officer

On a quest to revive the woolly mammoth, Colossal Biosciences has created a woolly mouse Read More »

Startup co-founded by longevity guru Peter Attia emerges from stealth

Biotech & Health /

Longevity is a hot trend in Silicon Valley these days, driven by rising interest—especially among the wealthy—in preventing disease through regular testing. A new player, Biograph, has just emerged from stealth, and it’s co-founded by one of the biggest names in longevity science: Dr. Peter Attia. Attia is a Canadian-American physician best known as the

Startup co-founded by longevity guru Peter Attia emerges from stealth Read More »

Stripe finalizes tender sale at a $91.5B valuation, says payment volumes grew to $1.4T in 2024

Biotech & Health /

Digital payments platform has yet to lay out plans to go public, but in the meantime the company has thrown past and present employees a line for some liquidity. The company on Thursday confirmed a tender offer where investors will buy up shares from those employees at a valuation of $91.5 billion. Stripe said it

Stripe finalizes tender sale at a $91.5B valuation, says payment volumes grew to $1.4T in 2024 Read More »